Neos Theraps Drug Patent Portfolio
Neos Theraps owns 1 orange book drug protected by 5 US patents Given below is the list of Neos Theraps's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8709491 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles | 28 Jun, 2032 | Active |
| US9017731 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles | 28 Jun, 2032 | Active |
| US9265737 | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles | 28 Jun, 2032 | Active |
| US9839619 | Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles | 28 Jun, 2032 | Active |
| US8840924 | Compositions and methods of making rapidly dissolving ionically masked formulations | 09 Apr, 2026 | Active |
Latest Legal Activities on Neos Theraps's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Neos Theraps.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 21 Oct, 2022 | US9017731 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 03 Jun, 2021 | US9839619 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 09 Apr, 2020 | US9017731 (Litigated) |
|
Email Notification
Critical
| 09 Apr, 2020 | US9839619 |
|
Email Notification
Critical
| 09 Apr, 2020 | US9017731 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 09 Apr, 2020 | US9839619 |
|
Correspondence Address Change
Critical
| 08 Apr, 2020 | US9017731 (Litigated) |
|
Correspondence Address Change
Critical
| 08 Apr, 2020 | US9839619 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 29 Oct, 2018 | US9017731 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Dec, 2017 | US9839619 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Dec, 2017 | US9839619 |
|
Issue Notification Mailed
Critical
| 21 Nov, 2017 | US9839619 |
| Dispatch to FDC | 13 Nov, 2017 | US9839619 |
|
Application Is Considered Ready for Issue
Critical
| 08 Nov, 2017 | US9839619 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 08 Nov, 2017 | US9839619 |
Neos Theraps's Family Patents
Neos Theraps drugs have patent protection in a total of 2 countries. It has a significant patent presence in the US with 94.4% of its patents being US patents. Click
below to unlock the full patent family tree.
Neos Theraps Drug List
Given below is the complete list of Neos Theraps's drugs and the patents protecting them.
1. Adzenys Xr-odt
Adzenys Xr-odt is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8709491 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
28 Jun, 2032
(7 years from now)
| Active |
| US9017731 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
28 Jun, 2032
(7 years from now)
| Active |
| US9265737 | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
28 Jun, 2032
(7 years from now)
| Active |
| US9839619 | Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles |
28 Jun, 2032
(7 years from now)
| Active |
| US8840924 | Compositions and methods of making rapidly dissolving ionically masked formulations |
09 Apr, 2026
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adzenys Xr-odt's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List